| http://purl.uniprot.org/citations/30910840 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/30910840 | http://www.w3.org/2000/01/rdf-schema#comment | "Prognostic significance of family with sequence similarity 83, member D (FAM83D) in hepatocellular carcinoma (HCC) patients has not been well-investigated using Gene Expression Omnibus (GEO) series and TCGA database, we compared FAM83D expression levels between tumor and adjacent tissues, and correlated FAM83D in tumors with outcomes and clinico-pathological features in HCC patients. Validated in GSE33006, GSE45436, GSE84402 and TCGA, FAM83D was significantly overexpressed in tumor tissues than that in adjacent tissues (all P<0.01). FAM83D up-regulation was significantly associated with worse overall survival (OS) and disease-free survival (DFS) in HCC patients (Log rank P=0.00583 and P=4.178E-04, respectively). Cox analysis revealed that FAM83D high expression was significantly associated with OS in HCC patients [hazard ratio (HR) = 1.44, 95% confidence interval (CI) = 1.005-2.063, P=0.047]. Additionally, patients deceased or recurred/progressed had significantly higher FAM83D mRNA levels than those living or disease-free (P=0.0011 and P=0.0238, respectively). FAM83D high expression group had significantly more male patients and advanced American Joint Committee on Cancer (AJCC) stage cases (P=0.048 and P=0.047, respectively). FAM83D mRNA were significantly overexpressed in male (P=0.0193). Compared with patients with AJCC stage I, those with AJCC stage II and stage III-IV had significantly higher FAM83D mRNA levels (P = 0.0346 and P=0.0045, respectively). In conclusion, overexpressed in tumors, FAM83D is associated with gender, AJCC stage, tumor recurrence and survival in HCC."xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://purl.org/dc/terms/identifier | "doi:10.1042/bsr20181640"xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://purl.uniprot.org/core/author | "Gao H."xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://purl.uniprot.org/core/author | "Liu X."xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://purl.uniprot.org/core/author | "Zhang J."xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://purl.uniprot.org/core/author | "Xue D."xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://purl.uniprot.org/core/date | "2019"xsd:gYear |
| http://purl.uniprot.org/citations/30910840 | http://purl.uniprot.org/core/name | "Biosci Rep"xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://purl.uniprot.org/core/pages | "BSR20181640"xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://purl.uniprot.org/core/title | "FAM83D is associated with gender, AJCC stage, overall survival and disease-free survival in hepatocellular carcinoma."xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://purl.uniprot.org/core/volume | "39"xsd:string |
| http://purl.uniprot.org/citations/30910840 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/30910840 |
| http://purl.uniprot.org/citations/30910840 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/30910840 |
| http://purl.uniprot.org/uniprot/#_A0A087WXK8-mappedCitation-30910840 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30910840 |
| http://purl.uniprot.org/uniprot/#_Q9H4H8-mappedCitation-30910840 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30910840 |
| http://purl.uniprot.org/uniprot/A0A087WXK8 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/30910840 |
| http://purl.uniprot.org/uniprot/Q9H4H8 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/30910840 |